Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(01): 114-119
DOI: 10.1055/s-0042-1742439
Brief Communication

How We Use Immunohistochemistry to Arrive at a Diagnosis in Breast Lesions

Ayushi Sahay
1   Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Asawari Patil
1   Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sangeeta B. Desai 
1   Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Immunohistochemistry (IHC) is an essential tool available to pathologists for facilitating diagnosis and as well as guiding the prognosis of breast lesions. Newer markers are increasingly being added to the pathologists' armamentarium. However, the selection and interpretation of the IHC markers should be judicious. In light of an appropriate morphological assessment, they should complement each other and produce accurate reports. We have briefly outlined here the immunohistochemical approach used in the diagnosis and management of breast cancers at our tertiary care cancer center.

Keywords

immunohistochemistry - breast cancer - biomarker - pathology

Authors' Contributions

AS was involved in conceptualization, designing, intellectual content, literature search, manuscript preparation, editing and review. SBD and AP contributed substantially in designing, intellectual content, manuscript editing and review.




Publication History

Article published online:
14 February 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Nair N, Shet T, Parmar V. et al. Breast cancer in a tertiary cancer center in India - an audit, with outcome analysis. Indian J Cancer 2018; 55 (01) 16-22
    CrossrefPubMedGoogle Scholar
  • 2 Rangarajan B, Shet T, Wadasadawala T. et al. Breast cancer: an overview of published Indian data. South Asian J Cancer 2016; 5 (03) 86-92
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Liu H. Application of immunohistochemistry in breast pathology: a review and update. Arch Pathol Lab Med 2014; 138 (12) 1629-1642
    CrossrefPubMedGoogle Scholar
  • 4 Peng Y, Butt YM, Chen B, Zhang X, Tang P. Update on immunohistochemical analysis in breast lesions. Arch Pathol Lab Med 2017; 141 (08) 1033-1051
    CrossrefPubMedGoogle Scholar
  • 5 Zaha DC. Significance of immunohistochemistry in breast cancer. World J Clin Oncol 2014; 5 (03) 382-392
    CrossrefPubMedGoogle Scholar
  • 6 Jorns JM. Papillary lesions of the breast: a practical approach to diagnosis. Arch Pathol Lab Med 2016; 140 (10) 1052-1059
    CrossrefPubMedGoogle Scholar
  • 7 Varga Z, Mallon E. Histology and immunophenotype of invasive lobular breast cancer. daily practice and pitfalls. Breast Dis 2008-2009–2009; 30: 15-19
    CrossrefPubMedGoogle Scholar
  • 8 Tse GM, Ni YB, Tsang JY. et al. Immunohistochemistry in the diagnosis of papillary lesions of the breast. Histopathology 2014; 65 (06) 839-853
    CrossrefPubMedGoogle Scholar
  • 9 Tay TKY, Tan PH. Spindle cell lesions of the breast - an approach to diagnosis. Semin Diagn Pathol 2017; 34 (05) 400-409
    CrossrefPubMedGoogle Scholar
  • 10 Rakha EA, Aleskandarany MA, Lee AH, Ellis IO. An approach to the diagnosis of spindle cell lesions of the breast. Histopathology 2016; 68 (01) 33-44
    CrossrefPubMedGoogle Scholar
  • 11 Allison KH, Hammond MEH, Dowsett M. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 2020; 38 (12) 1346-1366
    CrossrefPubMedGoogle Scholar
  • 12 Wolff AC, Hammond MEH, Allison KH. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol 2018; 36 (20) 2105-2122
    CrossrefPubMedGoogle Scholar
  • 13 Nielsen TO, Leung SCY, Rimm DL. et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2021; 113 (07) 808-819
    CrossrefPubMedGoogle Scholar
  • 14 Goldhirsch A, Winer EP, Coates AS. et al; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24 (09) 2206-2223
    CrossrefPubMedGoogle Scholar
  • 15 Cimino-Mathews A. Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls. Mod Pathol 2021; 34 (Suppl. 01) 62-77
    CrossrefPubMedGoogle Scholar
  • 16 Schmid P, Adams S, Rugo HS. et al; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379 (22) 2108-2121
    CrossrefPubMedGoogle Scholar
  • 17 Desai SB. Breast cancer pathology reporting in the Indian context: need for introspection. Indian J Pathol Microbiol 2020; 63 (Supplement): S3-S4
    CrossrefPubMedGoogle Scholar
  • 18 Shet T. Ki-67 in breast cancer: simulacra and simulation. Indian J Cancer 2020; 57 (03) 231-233
    PubMedGoogle Scholar
  • 19 Shet T. Improving accuracy of breast cancer biomarker testing in India. Indian J Med Res 2017; 146 (04) 449-458
    PubMedGoogle Scholar